Predictive cancer diagnostic technology company Rhythm Biosciences has boosted its cash position after completing the ...
D Path will use its AI-enabled platform to analyze H&E-stained tumor biopsy slides and identify biomarkers of response to an undisclosed Daiichi ADC program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results